Although increased systemic IL-17 production was associated with accelerated disease, the increase in systemic IL-4 (Figure 2b) was potentially surprising, in view of previous reports of the suppressive effects of IL-4-based therapies on arthritis and the known ability of IL-4 to suppress IL-17 responses in vitro. The gene discussed is IL17A; the disease is arthritic joint disease.